Results 201 to 210 of about 32,046 (240)
Some of the next articles are maybe not open access.
Acoramidis: A New Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy
Annals of PharmacotherapyObjective: The objective of the study was to review acoramidis, a new transthyretin stabilizer, for treatment of transthyretin amyloid cardiomyopathy by means of pharmacology, efficacy, and safety. Data sources: An Embase, PubMed, and ...
Taylor Clark +4 more
openaire +2 more sources
Transthyretin Cardiac Amyloidosis
Current Cardiology Reports, 2017Transthyretin (TTR)-related cardiac amyloidosis is a progressive infiltrative cardiomyopathy that mimics hypertensive, hypertrophic heart disease and may go undiagnosed. Transthyretin-derived amyloidosis accounts for 18% of all cases of cardiac amyloidosis.
Anit K, Mankad, Keyur B, Shah
openaire +2 more sources
Localization of transthyretin-mRNA and of immunoreactive transthyretin in the human fetus
Virchows Archiv A Pathological Anatomy and Histopathology, 1989Five human fetuses at mid-term (16-20 weeks) and one with a gestational age of 8 weeks were investigated. The cellular localization of transthyretin (TTR)-mRNA in different organs was demonstrated by in situ hybridization with a 35S-labelled, single-stranded RNA probe. Immunoreactive TTR (TTR-IR) was localized with a monoclonal antibody to TTR.
openaire +2 more sources
Tafamidis for transthyretin amyloidosis
Drugs of Today, 2012Tafamidis meglumine (Vyndaqel®, Pfizer) is a novel, first-in-class drug for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare neurodegenerative disorder characterized by progressive sensory, motor and autonomic impairment that is ultimately fatal.
openaire +2 more sources
Nursing, 2020
Abstract: Cardiac amyloidosis is a poorly understood cause of heart failure and is often undiagnosed. Recent advances in diagnostic testing and understanding of the disease have enhanced the ability of clinicians to detect this disease and provide patients with appropriate treatment.
openaire +2 more sources
Abstract: Cardiac amyloidosis is a poorly understood cause of heart failure and is often undiagnosed. Recent advances in diagnostic testing and understanding of the disease have enhanced the ability of clinicians to detect this disease and provide patients with appropriate treatment.
openaire +2 more sources
Transthyretin amyloid cardiomyopathy
Ugeskrift for LægerTransthyretin amyloidosis (ATTR-CM) is an infiltrative cardiomyopathy caused by the deposition of amyloid fibrils, leading to heart failure, arrhythmias, and increased mortality. ATTR-CM prevalence is rising. The first disease-modifying drugs have been approved and implemented in Denmark.
Sie Kronborg, Fensman +3 more
openaire +2 more sources
Cardiac transthyretin amyloidosis
Heart, 2012Cardiac amyloidosis of transthyretin fibril protein (ATTR) type is an infiltrative cardiomyopathy characterised by ventricular wall thickening and diastolic heart failure. Increased access to cardiovascular magnetic resonance imaging has led to a marked increase in referrals to our centre of Caucasian patients with wild-type ATTR (senile systemic ...
Jason N, Dungu +3 more
openaire +2 more sources
Hereditäre Transthyretin-Amyloidosen
Der Nervenarzt, 2014Hereditary amyloidosis is an autosomal dominant fatal multisystem disease caused by extracellular deposition of misfolded proteins and, therefore represents a hereditary protein folding or deposition disease that leads to progressive organ damage and eventually death.
openaire +2 more sources
Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism
International Journal of Molecular Sciences, 2021Jin Hae Kim
exaly